A Phase II, Randomised, Double-Blind, Dose-Ranging Study of AVX754 Versus Lamivudine in Treatment-Experienced HIV-1 Infected Patients With the M184V Mutation in Reverse Transcriptase.

Trial Profile

A Phase II, Randomised, Double-Blind, Dose-Ranging Study of AVX754 Versus Lamivudine in Treatment-Experienced HIV-1 Infected Patients With the M184V Mutation in Reverse Transcriptase.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Antiretrovirals; Apricitabine; Lamivudine
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Jul 2011 Australian New Zealand Clinical Trials Registry [ACTRN12605000742673] reports trial status recruiting.
    • 01 Jul 2011 Results published in HIV Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top